Second-line treatment with Axitinib: an effective and well-tolerated weapon in the therapeutic sequence of clear cell renal cell carcinoma. Working Paper of Public Health, [S. l.], v. 4, n. 1, 2015. DOI: 10.4081/wpph.2015.6697. Disponível em: https://journals.pagepress.org/wpph/article/view/6697. Acesso em: 19 jun. 2025.